150 related articles for article (PubMed ID: 10822468)
1. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection.
Itri LM; Campion M; Dennin RA; Palleroni AV; Gutterman JU; Groopman JE; Trown PW
Cancer; 1987 Feb; 59(3 Suppl):668-74. PubMed ID: 10822468
[TBL] [Abstract][Full Text] [Related]
2. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
3. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
Cancer; 1987 Feb; 59(3 Suppl):638-46. PubMed ID: 10822463
[TBL] [Abstract][Full Text] [Related]
4. Biology and therapy of epidemic Kaposi's sarcoma.
Groopman JE
Cancer; 1987 Feb; 59(3 Suppl):633-7. PubMed ID: 10822462
[TBL] [Abstract][Full Text] [Related]
5. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors.
Oberg K; Alm G
Biotherapy; 1997; 10(1):1-5. PubMed ID: 9261544
[TBL] [Abstract][Full Text] [Related]
6. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
Minasian LM; Motzer RJ; Gluck L; Mazumdar M; Vlamis V; Krown SE
J Clin Oncol; 1993 Jul; 11(7):1368-75. PubMed ID: 8315435
[TBL] [Abstract][Full Text] [Related]
7. Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors.
Krown SE; Real FX; Vadhan-Raj S; Cunningham-Rundles S; Krim M; Wong G; Oettgen HF
Cancer; 1986 Apr; 57(8 Suppl):1662-5. PubMed ID: 3081247
[TBL] [Abstract][Full Text] [Related]
8. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Goebel FD; Jablonowski H
Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
10. The detection of antibodies to recombinant interferon alfa-2a in human serum.
Hennes U; Jucker W; Fischer EA; Krummenacher T; Palleroni AV; Trown PW; Linder-Ciccolunghi S; Rainisio M
J Biol Stand; 1987 Jul; 15(3):231-44. PubMed ID: 3301856
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A).
Volberding PA; Mitsuyasu RT; Golando JP; Spiegel RJ
Cancer; 1987 Feb; 59(3 Suppl):620-5. PubMed ID: 3492260
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
Zouboulis CC; Orfanos CE
Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
Negrier S; Escudier B; Lasset C; Douillard JY; Savary J; Chevreau C; Ravaud A; Mercatello A; Peny J; Mousseau M; Philip T; Tursz T
N Engl J Med; 1998 Apr; 338(18):1272-8. PubMed ID: 9562581
[TBL] [Abstract][Full Text] [Related]
18. Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma.
Qureshi YA; Karp CL; Dubovy SR
Cornea; 2009 Sep; 28(8):941-3. PubMed ID: 19654515
[TBL] [Abstract][Full Text] [Related]
19. Recombinant interferon-alpha 2 antibodies in renal cell carcinoma. Delta-P Study Group.
Prümmer O; Porzsolt F
J Interferon Res; 1994 Aug; 14(4):193-5. PubMed ID: 7822873
[No Abstract] [Full Text] [Related]
20. Therapy of chronic myelogenous leukemia.
Talpaz M; Kantarjian H; McCredie K; Trujillo J; Keating M; Gutterman JU
Cancer; 1987 Feb; 59(3 Suppl):664-7. PubMed ID: 10822467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
